76.91

1.20% 1.01

Bio Techne Corp (TECH)

Overview News Price History Option Chain Financials Discussions Forecast Stock Split Dividend History

Bio Techne Corp stock is traded at $76.91, with a volume of 174.84K. It is up +1.20% in the last 24 hours and up +2.71% over the past month. Based in Minnesota, Bio-Techne is a life sciences manufacturer supplying consumables and instruments for the pharma, biotech, academic, and diagnostic markets. It reports in two segments: protein sciences (75% of revenue) and diagnostics and genomics (25%). The protein sciences segment sells reagents and analytical instruments used in life sciences research, including antibodies used in protein analysis. The diagnostics and genomics segment sells diagnostic reagents, molecular diagnostics, and spatial biology products. The United States accounts for about 55% of revenue. The firm also has operations in Europe, the Middle East, and Africa (20% of sales), the UK (5%), and Asia-Pacific (15%), with the rest of the world accounting for the remaining 5%.

Previous Close:

$75.90

Open:

$74.91

24h Volume:

174.84K

Relative Volume:

0.20

Market Cap:

$12.15B

Revenue:

$1.16B

Net Income/Loss:

$168.11M

P/E Ratio:

50.60

EPS:

1.52

Net Cash Flow:

$236.10M

1W Performance:

+8.58%

1M Performance:

+2.71%

6M Performance:

-0.62%

1Y Performance:

+30.80%

1-Day Range:

$73.92

$76.95

1-Week Range:

$73.75

$79.46

52-Week Range:

$55.63

$85.57

Bio Techne Corp Stock (TECH) Company Profile

Name

Bio Techne Corp

Sector

Healthcare (1181)

Industry

Biotechnology (680)

Phone

(612) 379-8854

Address

614 MCKINLEY PL N E, MINNEAPOLIS, MN

Employee

3,100

Twitter

@biotechne

Next Earnings Date

2024-10-30

Latest SEC Filings

TECH's Discussions on Twitter

Bio Techne Corp Stock (TECH) Upgrades & Downgrades

Date	Action	Analyst	Rating Change
May-22-24	Downgrade	Citigroup	Buy → Neutral
Feb-08-24	Initiated	Scotiabank	Sector Outperform
Feb-02-24	Downgrade	Stifel	Buy → Hold
Dec-07-23	Initiated	UBS	Buy
Aug-28-23	Initiated	William Blair	Outperform
Jan-10-23	Upgrade	Wells Fargo	Underweight → Equal Weight
Dec-14-22	Initiated	Deutsche Bank	Buy
Dec-12-22	Upgrade	Citigroup	Neutral → Buy
Dec-07-22	Initiated	RBC Capital Mkts	Sector Perform
Aug-25-22	Initiated	Credit Suisse	Outperform
Apr-25-22	Downgrade	Wells Fargo	Equal Weight → Underweight
Sep-15-21	Upgrade	KeyBanc Capital Markets	Sector Weight → Overweight
Mar-08-21	Upgrade	Stephens	Equal-Weight → Overweight
Feb-23-21	Upgrade	Stifel	Hold → Buy
Jan-25-21	Reiterated	The Benchmark Company	Buy
Nov-10-20	Initiated	KeyBanc Capital Markets	Sector Weight
Sep-30-20	Initiated	Atlantic Equities	Overweight
Jul-15-20	Downgrade	Stephens	Overweight → Equal-Weight
May-27-20	Downgrade	Stifel	Buy → Hold
May-14-20	Initiated	The Benchmark Company	Buy
Jan-08-20	Resumed	Stephens	Overweight
Jan-08-20	Initiated	Wells Fargo	Equal Weight
Jan-07-20	Initiated	Citigroup	Neutral
Nov-15-19	Initiated	Stifel	Buy
Jul-02-19	Upgrade	Janney	Neutral → Buy
Jan-14-19	Upgrade	Stephens	Equal-Weight → Overweight
Oct-31-18	Downgrade	Craig Hallum	Buy → Hold
Oct-17-18	Initiated	Goldman	Neutral
Jun-15-18	Initiated	Argus	Buy
Jul-13-17	Initiated	Wells Fargo	Market Perform
Feb-09-17	Initiated	Citigroup	Buy
Jan-18-17	Initiated	Deutsche Bank	Buy
Nov-10-16	Resumed	Leerink Partners	Outperform
Jan-21-15	Reiterated	Robert W. Baird	Outperform
Sep-20-13	Upgrade	Robert W. Baird	Neutral → Outperform

View All

Bio Techne Corp Stock (TECH) Latest News

07:00 AM

LUNAPHORE COMET™ PLATFORM PAVES THE WAY FOR SPATIAL BIOLOGY ADOPTION IN CLINICAL RESEARCH - Yahoo Finance

07:00 AM

04:49 AM

Bio-Techne Co. (NASDAQ:TECH) Receives Consensus Recommendation of "Moderate Buy" from Analysts - MarketBeat

04:49 AM

Nov 04, 2024

Bio-Techne Tops Q1 Earnings & Revenue Estimates, Stock Up in Premarket - MSN

Nov 04, 2024